Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tevogen Bio Holdings Inc. - Common Stock
(NQ:
TVGN
)
0.3851
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 22, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tevogen Bio Holdings Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas
October 25, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Capri, Coursera, DexCom And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
October 25, 2024
Via
Benzinga
Early Movers: PRSO, TVGN, ZENA, CCTG, CRDL Stocks to Watch Today!
October 24, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 24, 2024
Via
Benzinga
Tevogen Bio Shares Are Soaring Wednesday: What's Going On?
↗
October 23, 2024
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) stock is moving higher on Wednesday after the company announced its artificial intelligence effort, Tevogen AI, has joined Microsoft Corporation (NASDAQ:MSFT)...
Via
Benzinga
Topics
Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
October 23, 2024
Via
Benzinga
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development
October 23, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week
October 22, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
October 21, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days
October 21, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days
October 18, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
↗
October 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
October 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
October 17, 2024
Via
Benzinga
Why Is Small-Cap Tevogen Bio Stock Rocketing Higher On Thursday?
↗
October 17, 2024
evogen Bio projects strong revenue for its oncology pipeline and reports positive phase 1 trial data for its COVID-19 therapy. The company's stock is trading higher amid increased volume.
Via
Benzinga
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
October 17, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion
October 17, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality
October 16, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
October 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
October 15, 2024
Via
Benzinga
Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions
October 15, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for
October 15, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
↗
October 15, 2024
Via
Benzinga
Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections
October 14, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Dow Surges Over 200 Points; Longboard Pharmaceuticals Shares Jump
↗
October 14, 2024
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
↗
October 14, 2024
Via
Benzinga
Crude Oil Down Over 2%; Verb Technology Shares Spike Higher
↗
October 14, 2024
Via
Benzinga
Leaders in The News: BigBear.ai, Luminar, New World Solutions, Tevogen Bio
October 14, 2024
Latest Advances in AI for Military, Biotech, Electric Vehicles and Digital Transformation of $31 Billion Watch Market
Via
News Direct
Topics
Artificial Intelligence
Nasdaq Surges 1%; Boeing Reports 10% Workforce Reduction
↗
October 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
October 14, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
